Tirzepatide is a dual GLP-1/GIP receptor agonist that has generated one of the largest bodies of clinical research data among modern metabolic peptides. Its dual mechanism of action differentiates it from single-receptor GLP-1 agonists.
Dual Mechanism: GLP-1 and GIP
Tirzepatide simultaneously activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is the other major incretin hormone and complements GLP-1's effects through distinct but complementary pathways, including direct effects on adipose tissue and potentially enhanced insulin sensitization.
SURPASS Research Program (Diabetes)
The SURPASS trials evaluated tirzepatide across multiple doses (5, 10, and 15 mg weekly) in type 2 diabetes. SURPASS-2 compared tirzepatide directly to semaglutide 1 mg and demonstrated superior HbA1c reductions and weight loss at all doses, with the 15 mg dose achieving a mean HbA1c reduction of 2.46% versus 1.86% for semaglutide.
SURMOUNT Research Program (Obesity)
The SURMOUNT-1 trial evaluated tirzepatide 5, 10, and 15 mg in adults with obesity. The 15 mg dose achieved a mean weight reduction of approximately 22.5% from baseline over 72 weeks — exceeding even the impressive results seen with semaglutide 2.4 mg and representing the largest weight reduction demonstrated by a pharmaceutical agent in a pivotal obesity trial to date.
FDA Approval Status
Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023, making it the first dual incretin agonist approved for both indications.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.